Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 10, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-33133 | |
Entity Registrant Name | YIELD10 BIOSCIENCE, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 04-3158289 | |
Entity Address, Address Line One | 19 Presidential Way | |
Entity Address, City or Town | Woburn | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 01801 | |
City Area Code | 617 | |
Local Phone Number | 583-1700 | |
Title of 12(b) Security | Common Stock | |
Trading Symbol | YTEN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 4,944,202 | |
Entity Central Index Key | 0001121702 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue: | ||||
Revenue | $ 111 | $ 92 | $ 363 | $ 462 |
Expenses: | ||||
Research and development | 2,083 | 1,636 | 5,862 | 4,603 |
General and administrative | 1,518 | 1,547 | 4,748 | 4,583 |
Total expenses | 3,601 | 3,183 | 10,610 | 9,186 |
Loss from operations | (3,490) | (3,091) | (10,247) | (8,724) |
Other income (expense): | ||||
Gain on investment in related party | 0 | 700 | 0 | 700 |
Other income (expense), net | 10 | (1) | 11 | (2) |
Total other income (expense) | 10 | 699 | 11 | 698 |
Loss from operations before income taxes | (3,480) | (2,392) | (10,236) | (8,026) |
Income tax provision | (9) | (6) | (27) | (25) |
Net loss | $ (3,489) | $ (2,398) | $ (10,263) | $ (8,051) |
Basic net loss per share (in USD per share) | $ (0.71) | $ (0.49) | $ (2.09) | $ (1.72) |
Diluted net loss per share (in USD per share) | $ (0.71) | $ (0.49) | $ (2.09) | $ (1.72) |
Number of shares used in per share calculations: | ||||
Basic (in shares) | 4,924,606 | 4,873,248 | 4,904,737 | 4,681,292 |
Diluted (in shares) | 4,924,606 | 4,873,248 | 4,904,737 | 4,681,292 |
Grant | ||||
Revenue: | ||||
Revenue | $ 111 | $ 92 | $ 363 | $ 462 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current Assets: | ||
Cash and cash equivalents | $ 3,922 | $ 5,329 |
Short-term investments | 3,483 | 10,661 |
Accounts receivable | 37 | 164 |
Unbilled receivables | 39 | 34 |
Prepaid expenses and other current assets | 414 | 436 |
Total current assets | 7,895 | 16,624 |
Restricted cash | 264 | 264 |
Property and equipment, net | 840 | 890 |
Right-of-use assets | 2,063 | 2,354 |
Other assets | 210 | 283 |
Total assets | 11,272 | 20,415 |
Current Liabilities: | ||
Accounts payable | 104 | 83 |
Accrued expenses | 1,163 | 1,136 |
Current portion of lease liabilities | 559 | 514 |
Total current liabilities | 1,826 | 1,733 |
Lease liabilities, net of current portion | 2,226 | 2,656 |
Total liabilities | 4,052 | 4,389 |
Commitments and contingencies (Note 9) | ||
Stockholders’ Equity: | ||
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock ($0.01 par value per share); 60,000,000 shares authorized at September 30, 2022 and December 31, 2021; 4,933,288 and 4,881,851 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | 49 | 49 |
Additional paid-in capital | 403,799 | 402,283 |
Accumulated other comprehensive loss | (234) | (175) |
Accumulated deficit | (396,394) | (386,131) |
Total stockholders’ equity | 7,220 | 16,026 |
Total liabilities and stockholders’ equity | $ 11,272 | $ 20,415 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value per share (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, issued (in shares) | 0 | 0 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Common stock, par value per share (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, authorized (in shares) | 60,000,000 | 60,000,000 |
Common stock, issued (in shares) | 4,933,288 | 4,881,851 |
Common stock, outstanding (in shares) | 4,933,288 | 4,881,851 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS UNAUDITED - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Statement of Comprehensive Income [Abstract] | ||||
Net loss | $ (3,489) | $ (2,398) | $ (10,263) | $ (8,051) |
Other comprehensive loss | ||||
Change in unrealized loss on investments | 20 | 0 | (2) | 1 |
Change in foreign currency translation adjustment, net of income tax | (34) | (17) | (57) | (12) |
Total other comprehensive loss | (14) | (17) | (59) | (11) |
Comprehensive loss | $ (3,503) | $ (2,415) | $ (10,322) | $ (8,062) |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities | ||
Net loss | $ (10,263) | $ (8,051) |
Adjustments to reconcile net loss to cash used in operating activities: | ||
Depreciation and amortization | 197 | 165 |
Charge for 401(k) company common stock match | 111 | 100 |
Stock-based compensation | 1,458 | 1,175 |
Non-cash lease expense | 291 | 265 |
Deferred income tax provision | 37 | 24 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 127 | 62 |
Unbilled receivables | (5) | (19) |
Prepaid expenses and other assets | 52 | 60 |
Accounts payable | 21 | (15) |
Accrued expenses | 17 | (192) |
Lease liabilities | (385) | (342) |
Net cash used in operating activities | (8,342) | (6,768) |
Cash flows from investing activities | ||
Purchase of property and equipment | (154) | (147) |
Purchase of investments | (1,195) | (3,874) |
Proceeds from the maturity of short-term investments | 8,371 | 6,250 |
Net cash provided by investing activities | 7,022 | 2,229 |
Cash flows from financing activities | ||
Proceeds from warrants exercised | 0 | 3,856 |
Proceeds from public offering, net of issuance costs | 0 | 11,993 |
Taxes paid on employees' behalf related to vesting of stock awards | (37) | (103) |
Net cash (used in) provided by financing activities | (37) | 15,746 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (50) | (12) |
Net (decrease) increase in cash, cash equivalents and restricted cash | (1,407) | 11,195 |
Cash, cash equivalents and restricted cash at beginning of period | 5,593 | 3,687 |
Cash, cash equivalents and restricted cash at end of period | $ 4,186 | $ 14,882 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit |
Balance (in shares) at Dec. 31, 2020 | 3,334,048 | ||||
Balance at Dec. 31, 2020 | $ 9,532 | $ 33 | $ 384,758 | $ (159) | $ (375,100) |
Increase (decrease) in stockholders' equity | |||||
Stock-based compensation expense | 1,185 | 1,185 | |||
Issuance of common stock for 401k match (in shares) | 9,747 | ||||
Issuance of common stock for 401(k) match | 86 | 86 | |||
Issuance of common stock for restricted stock units (in shares) | 12,219 | ||||
Taxes paid on employees' behalf related to vesting of stock awards | (102) | (102) | |||
Issuance of common stock for warrant exercises (in shares) | 481,973 | ||||
Issuance of common stock for warrant exercises | 3,856 | $ 5 | 3,851 | ||
Issuance of common stock in connection with stock offering, net of offering costs (in shares) | 1,040,000 | ||||
Issuance of common stock in connection with stock offering, net of offering costs | 11,993 | $ 11 | 11,982 | ||
Effect of foreign currency translation and unrealized loss on investments | (11) | (11) | |||
Net loss | (8,051) | (8,051) | |||
Balance (in shares) at Sep. 30, 2021 | 4,877,987 | ||||
Balance at Sep. 30, 2021 | 18,488 | $ 49 | 401,760 | (170) | (383,151) |
Balance (in shares) at Jun. 30, 2021 | 4,868,466 | ||||
Balance at Jun. 30, 2021 | 20,462 | $ 49 | 401,319 | (153) | (380,753) |
Increase (decrease) in stockholders' equity | |||||
Stock-based compensation expense | 436 | 436 | |||
Issuance of common stock for 401k match (in shares) | 2,857 | ||||
Issuance of common stock for 401(k) match | 24 | 24 | |||
Issuance of common stock for restricted stock units (in shares) | 6,664 | ||||
Taxes paid on employees' behalf related to vesting of stock awards | (19) | (19) | |||
Effect of foreign currency translation and unrealized loss on investments | (17) | (17) | |||
Net loss | (2,398) | (2,398) | |||
Balance (in shares) at Sep. 30, 2021 | 4,877,987 | ||||
Balance at Sep. 30, 2021 | 18,488 | $ 49 | 401,760 | (170) | (383,151) |
Balance (in shares) at Dec. 31, 2021 | 4,881,851 | ||||
Balance at Dec. 31, 2021 | 16,026 | $ 49 | 402,283 | (175) | (386,131) |
Increase (decrease) in stockholders' equity | |||||
Stock-based compensation expense | 1,458 | 1,458 | |||
Issuance of common stock for 401k match (in shares) | 25,792 | ||||
Issuance of common stock for 401(k) match | 95 | 95 | |||
Issuance of common stock for restricted stock units (in shares) | 25,645 | ||||
Taxes paid on employees' behalf related to vesting of stock awards | (37) | (37) | |||
Effect of foreign currency translation and unrealized loss on investments | (59) | (59) | |||
Net loss | (10,263) | (10,263) | |||
Balance (in shares) at Sep. 30, 2022 | 4,933,288 | ||||
Balance at Sep. 30, 2022 | 7,220 | $ 49 | 403,799 | (234) | (396,394) |
Balance (in shares) at Jun. 30, 2022 | 4,901,246 | ||||
Balance at Jun. 30, 2022 | 10,271 | $ 49 | 403,347 | (220) | (392,905) |
Increase (decrease) in stockholders' equity | |||||
Stock-based compensation expense | 446 | 446 | |||
Issuance of common stock for 401k match (in shares) | 12,875 | ||||
Issuance of common stock for 401(k) match | 29 | 29 | |||
Issuance of common stock for restricted stock units (in shares) | 19,167 | ||||
Taxes paid on employees' behalf related to vesting of stock awards | (23) | (23) | |||
Effect of foreign currency translation and unrealized loss on investments | (14) | (14) | |||
Net loss | (3,489) | (3,489) | |||
Balance (in shares) at Sep. 30, 2022 | 4,933,288 | ||||
Balance at Sep. 30, 2022 | $ 7,220 | $ 49 | $ 403,799 | $ (234) | $ (396,394) |
ACCOUNTING POLICIES
ACCOUNTING POLICIES | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
ACCOUNTING POLICIES | ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, including accounting standards set by the Financial Accounting Standards Board ("FASB"). The FASB sets GAAP that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the unaudited condensed consolidated financial statements are to the ASC. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, YOI and Yield10 Bioscience Securities Corp. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein: September 30, December 31, Cash and cash equivalents $ 3,922 $ 5,329 Restricted cash 264 264 Total cash, cash equivalents and restricted cash $ 4,186 $ 5,593 Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $264 at September 30, 2022 and December 31, 2021 consists primarily of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility. Investments The Company classifies investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. The Company classifies investments with a maturity date of greater than one year from the balance sheet date as long-term investments. Other-than-temporary impairments of equity investments are recognized in the Company's unaudited condensed consolidated statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates. Foreign Currency Translation The functional currency for YOI is the Canadian dollar. Foreign denominated assets and liabilities of YOI are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the unaudited condensed consolidated balance sheet. When the Company dissolves, sells all or substantially all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its unaudited condensed consolidated statement of operations during the fiscal period when the dissolution or sale occurs. Comprehensive Loss Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss. Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the unaudited condensed consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized. The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. At September 30, 2022, all of the Company's accounts and unbilled receivables of $76 were due from Michigan State University ("MSU") for support to a Department of Energy ("DOE") funded grant under which the Company serves as a subcontractor. The Company believes these receivables have a low risk of default. At December 31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from MSU for support to the DOE grant. Fair Value Measurements The carrying amounts of the Company's financial instruments as of September 30, 2022 and December 31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 5 for further discussion on fair value measurements. Segment Information The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows: Asset Description Estimated Useful Life (years) Equipment 3 Furniture and fixtures 5 Software 3 Leasehold improvements Shorter of useful life or term of lease Lease Accounting As a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842. Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset. Grant Revenue The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered a central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying unaudited condensed consolidated balance sheets at September 30, 2022 and December 31, 2021. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned. Research and Development All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation. Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory. Costs incurred in connection with government research grants are recorded as research and development expense. General and Administrative Expenses The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation, stock-based compensation and office related expenses incurred to support the administrative and business development of the Company. Intellectual Property Costs The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the Company's unaudited condensed consolidated statements of operations. Stock-Based Compensation All share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expenses based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 7 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding. Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance . This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU is effective for annual periods beginning after December 15, 2021. The adoption of this standard has not materially impacted the Company’s condensed consolidated financial statements in 2022. The following new pronouncement is not yet effective but may impact the Company's unaudited condensed consolidated financial statements in the future. In June 2016, the FASB issued A SU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition , and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its unaudited condensed consolidated financial statements. |
NATURE OF BUSINESS AND BASIS OF
NATURE OF BUSINESS AND BASIS OF PRESENTATION | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NATURE OF BUSINESS AND BASIS OF PRESENTATION | NATURE OF BUSINESS AND BASIS OF PRESENTATION Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address: • petroleum replacement markets, in which the Company is developing Camelina oil for use as a biofuel feedstock and PHA Bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and • food and nutrition markets, in which the Company is developing omega-3 (EPA, DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets. Yield10 also plans to license yield and seed oil traits from the Company's pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, Massachusetts, and has an Oilseed Center of Excellence located in Saskatoon, Saskatchewan, Canada. Yield10's wholly-owned Canadian subsidiary, Metabolix Oilseeds Inc., changed its name to Yield10 Oilseeds Inc. ("YOI") effective July 12, 2022, in order to better align the name with the Company's branding. The accompanying condensed consolidated financial statements are presented in U.S. dollars, are unaudited, and have been prepared by Yield10 in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The condensed consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for fair statement of the financial position as of September 30, 2022 and December 31, 2021, and for the results of operations for the interim periods ended September 30, 2022 and September 30, 2021. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021, which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2022. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including the three and nine months ended September 30, 2022. As of September 30, 2022, the Company held unrestricted cash, cash equivalents and investments of $7,405. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern , in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its condensed consolidated financial statements are issued. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment. Based on the Company's current cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from when these condensed consolidated financial statements are available to be issued, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors. If the Company issues equity or debt securities to raise additional funds in the future, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company. In February 2022, Russia initiated a military offensive in Ukraine which has resulted in significant uncertainty in the commodities market. The scope, intensity, duration and outcome of the ongoing war, resulting sanctions and resulting future market disruptions is uncertain and its continuation or escalation may have a material adverse effect on the Company. Ukraine, and the Black Sea region in general, are a major exporter of wheat and corn to the world, and the disruption of supply could cause volatility in prices and margins of these commodities and related products. Ukraine is also the largest supplier of sun seed and sun oil in the world which cannot be completely replaced from other geographic regions. The conflict in Ukraine has created disruptions in global supply chains and is expected to create dislocations of key agricultural commodities. While Yield10 has no direct business operations or assets within either Ukraine or Russia, the Company's plans and operating results could be adversely affected by a number of factors, including the crop growing decisions made by farmers in the U.S., Canada and South America as a consequence of supply shortages and rising commodity prices. These rising prices may negatively impact the Company's ability to contract suitable acreage for future crop trials or could delay its plans to commercialize Yield10's first Camelina plant varieties. The Company’s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including changes in inflation, interest rates and overall economic conditions and uncertainties. For instance, for the twelve months ended September 30, 2022, the U.S. Bureau of Labor Statistics reported that the Consumer Price Index for All Urban Consumers increased 8.2 percent. If the inflation rate continues to increase, for example due to increases in the costs of labor and supplies, it will affect the Company's expenses and it might make it more expensive for the Company to continue its research and development. Inflation could also adversely affect the ability of growers to enter into and fulfill their obligations under Camelina grain production agreements with the Company. The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain. While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce. Given the evolving nature of the COVID-19 pandemic and the global responses to it, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for future periods. |
BASIC AND DILUTED NET LOSS PER
BASIC AND DILUTED NET LOSS PER SHARE | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
BASIC AND DILUTED NET LOSS PER SHARE | BASIC AND DILUTED NET LOSS PER SHARE Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. Common stock equivalents include stock options, restricted stock awards and warrants. The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect: As of September 30, 2022 2021 Options 953,787 716,619 Restricted Stock Awards 27,123 9,430 Warrants 1,290,273 2,361,726 Total 2,271,183 3,087,775 |
INVESTMENTS
INVESTMENTS | 9 Months Ended |
Sep. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
INVESTMENTS | INVESTMENTS Investments consist of the following at September 30, 2022 and December 31, 2021: Accumulated Cost at September 30, 2022 Unrealized Market Value at September 30, 2022 Gain (Loss) Short-term investments U.S. government and agency securities $ 3,493 $ — $ (10) $ 3,483 Total $ 3,493 $ — $ (10) $ 3,483 Accumulated Cost at December 31, 2021 Unrealized Market Value at December 31, 2021 Gain (Loss) Short-term investments U.S. government and agency securities $ 10,669 $ — $ (8) $ 10,661 Total $ 10,669 $ — $ (8) $ 10,661 All investments are classified as available for sale as of September 30, 2022 and December 31, 2021. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input. The Company’s financial assets classified as Level 2 at September 30, 2022 and December 31, 2021 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of September 30, 2022 and December 31, 2021. The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. Fair value measurements at reporting date using Quoted prices in active markets for identical Significant other Significant Balance as of Description (Level 1) (Level 2) (Level 3) September 30, 2022 Cash equivalents: Money market funds $ 2,594 $ — $ — $ 2,594 Short-term investments: U.S. government and agency securities — 3,483 — 3,483 Total assets $ 2,594 $ 3,483 $ — $ 6,077 Fair value measurements at reporting date using Quoted prices in active markets for identical Significant other Significant Balance as of Description (Level 1) (Level 2) (Level 3) December 31, 2021 Cash equivalents: Money market funds $ 4,878 $ — $ — $ 4,878 Short-term investments: U.S. government and agency securities — 10,661 — 10,661 Total assets $ 4,878 $ 10,661 $ — $ 15,539 There were no transfers of financial assets between category levels during the three and nine months ended September 30, 2022 and the three and nine months ended September 30, 2021. |
ACCRUED EXPENSES
ACCRUED EXPENSES | 9 Months Ended |
Sep. 30, 2022 | |
Payables and Accruals [Abstract] | |
ACCRUED EXPENSES | ACCRUED EXPENSES Accrued expenses consisted of the following at: September 30, December 31, Employee compensation and benefits $ 386 $ 452 Leased facilities 61 71 Professional services 237 264 Field trials and related expenses 342 97 Other 137 252 Total accrued expenses $ 1,163 $ 1,136 |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION Expense Information for Employee and Non-Employee Stock Awards The Company recognized stock-based compensation expense related to stock awards, including awards to non-employees and members of the Board of Directors, of $447 and $1,458 for the three and nine months ended September 30, 2022, respectively, and $436 and $1,175 for the three and nine months ended September 30, 2021, respectively. At September 30, 2022, there was approximately $3,567 of unvested awards not yet recognized as compensation expense. The compensation expense related to unvested stock awards is expected to be recognized over a remaining weighted average period of 2.58 years. Stock Options A summary of option activity for the nine months ended September 30, 2022 is as follows: Number of Weighted Average Outstanding at December 31, 2021 722,765 $ 19.22 Granted 233,086 3.83 Exercised — — Forfeited (1,859) 7.55 Expired (205) 4,816.86 Outstanding at September 30, 2022 953,787 $ 14.45 Options exercisable at September 30, 2022 377,807 $ 25.59 In accordance with the terms of the Company's 2018 Stock Option and Incentive Plan ("2018 Stock Plan"), effective January 1, 2022 and January 1, 2021, Yield10's Board of Directors approved the addition of 244,092 shares and 166,702 shares, respectively, to the 2018 Stock Plan, which represented 5% of the Company's outstanding common stock on the day prior to each increase. At its annual meeting of stockholders on May 24, 2021, stockholders approved an amendment to the 2018 Stock Plan to add 300,000 more shares to the plan. As of September 30, 2022, 25,961 shares remain available to be awarded from the 2018 Stock Plan. Restricted Stock Units The Company records stock compensation expense for restricted stock units ("RSUs") on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date fair market value. As RSUs vest, the Company withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount from the common stock issuable at the vest date. During the nine months ended September 30, 2022, 36,557 employee RSUs vested, of which 10,912 common shares with a total market value of $34 were withheld to pay employee tax withholding. A summary of RSU activity for the nine months ended September 30, 2022 is as follows: Number of RSUs Weighted Average Remaining Contractual Life (years) Outstanding at December 31, 2021 9,430 Awarded 54,250 Released (36,557) Outstanding at September 30, 2022 27,123 0.36 |
LEASES
LEASES | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
LEASES | LEASES Maturity Analysis of Lease Liabilities The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities. No other active real estate or equipment leases fall within the scope of ASC 842. At September 30, 2022, the Company's lease liability related to its Woburn facility will mature as follows: Year ended December 31, Undiscounted Cash Flows 2022 (October to December) $ 183 2023 749 2024 771 2025 793 2026 747 Total undiscounted future lease payments 3,243 Amount of lease payments representing interest (460) Total lease liabilities $ 2,783 Short-term lease liability $ 559 Long-term lease liability $ 2,224 Quantitative Disclosure of Lease Costs Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease cost: Operating lease cost $ 151 $ 151 $ 454 $ 454 Short-term lease cost 177 171 509 497 Sublease income (155) (148) (450) (468) Total lease cost, net $ 173 $ 174 $ 513 $ 483 Other information as of: September 30, 2022 December 31, 2021 Weighted-average remaining lease term (years) 4.2 4.9 Weighted-average discount rate 7.25% 7.25% Real Estate Leases During 2016, the Company entered into a lease agreement, as amended, for its headquarters pursuant to which the Company leases 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease agreement will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain pro rata taxes and operating costs associated with the premises throughout the term of the lease. During the initial buildout of the rented space, the landlord paid for certain tenant improvements that resulted in increased rental payments by the Company. As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset. The Company has provided the landlord with a security deposit of $229. In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The CJ sublease is coterminous with the Company's master lease and CJ will pay rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $3,243 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit. The Company's wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 8,600 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. YOI's leases for these facilities expire on various dates through May 2023. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Contractual Commitments Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted") In November 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted’s program to develop omega-3 oils in Camelina sativa. Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further EPA, DHA+EPA trait improvement, field testing and nutritional studies. The Company is paying Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $31 remained outstanding as of September 30, 2022. As part of the agreement, the Company had an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology. In November 2022, Yield10 and Rothamsted agreed to extend the collaboration agreement, including the license option, without additional funding support, through December 31, 2023. License Agreement with the University of Missouri ("UM") Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops. Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production. The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops. Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone. The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products. The Company or UM may terminate the license agreement in accordance with the terms of the agreement. Guaranteed Minimum Payments to Growers. As an incentive for growers located in Canada and the U.S. to enter into Camelina commercial grain production contracts with the Company for the 2022/2023 winter season, Yield10 has offered minimum guaranteed payments per acre that reduce a grower's risk of financial loss. These minimum payments are conditional upon a grower fulfilling their contractual responsibilities and are reduced by the price of Yield10's Camelina planting seed and the contractual price that the Company will pay for the actual amount of grain that is harvested. Although the Company anticipates that the payment of these guaranteed amounts will not be required under normal growing conditions, for the 2022/2023 winter season the maximum amount of these grain production guarantees approximates $320. Facility Leases The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026. See Note 8. Litigation From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Guarantees As of September 30, 2022 and December 31, 2021, the Company did not have significant liabilities recorded for guarantees. The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of September 30, 2022 and December 31, 2021. |
LICENSE AGREEMENTS
LICENSE AGREEMENTS | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
LICENSE AGREEMENTS | LICENSE AGREEMENTS In September 2017, the Company granted a license to Bayer to evaluate the Company's novel C3003 and C3004 yield traits in soybean. Under this license, Bayer has the non-exclusive right to begin work with C3003 in its soybean program as a strategy to improve seed yield. Bayer may also conduct research with the Company's C3004 yield trait, a trait accessible through genome editing, in combination with C3003 to evaluate the effectiveness of the combination in improving seed yield in soybean. In August 2019, the Company expanded the license with Bayer to include a new discovery related to the Company's C3004 yield trait gene. In September 2018, the Company granted a four-year, non-exclusive license, as amended, to Forage Genetics International, LLC, a subsidiary of Land O'Lakes, Inc., to evaluate five of the Company's novel traits in forage sorghum. The traits included in the research license include C3003 as well as four traits from the Company's GRAIN platform; C4001, C4002, C4003 and C4029. In September 2022, the license terminated in accordance with its terms. In October 2019, the Company granted a non-exclusive license to J. R. Simplot ("Simplot"), to evaluate three of the Company's novel traits in potato. Under the license agreement, Simplot plans to conduct research with the yield traits C3003, C3004 and C4001 within its research and development program as a strategy to improve crop performance and sustainability. In September 2022, the Company and Simplot amended the license agreement in order to extend it for a fourth year. In August 2020, the Company entered into a non-exclusive research agreement with GDM ("GDM"), a company specializing in plant genetics, to evaluate novel traits in soybean. Under the terms of the agreement, GDM is working with the Company's yield traits within its research and development program as a strategy to improve soybean yield performance and sustainability. The research agreement includes three novel yield traits in the first phase with the potential to expand the program to more traits in the future. None of these research arrangements provides significant licensing revenue to the Company while the third parties perform trait evaluations. |
GEOGRAPHIC INFORMATION
GEOGRAPHIC INFORMATION | 9 Months Ended |
Sep. 30, 2022 | |
Segment Reporting [Abstract] | |
GEOGRAPHIC INFORMATION | GEOGRAPHIC INFORMATION The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below. Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled. U.S. Canada Total Three Months Ended September 30, 2022 Revenue $ 111 $ — $ 111 Three Months Ended September 30, 2021 Revenue $ 92 $ — $ 92 Nine Months Ended September 30, 2022 Revenue $ 363 $ — $ 363 Nine Months Ended September 30, 2021 Revenue $ 423 $ 39 $ 462 Identifiable long-lived assets September 30, 2022 $ 722 $ 118 $ 840 September 30, 2021 $ 850 $ 53 $ 903 |
CAPITAL STOCK AND WARRANTS
CAPITAL STOCK AND WARRANTS | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
CAPITAL STOCK AND WARRANTS | CAPITAL STOCK AND WARRANTS Common Stock Registered Public Offerings On February 3, 2021, the Company completed a public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share for total gross proceeds of $12,740 before issuance costs of $747. Preferred Stock The Company's Certificate of Incorporation authorizes the Company to issue up to 5,000,000 shares of $0.01 par value preferred stock. Warrants The following table summarizes information regarding outstanding warrants to purchase common stock as of September 30, 2022: Issuance Number of Shares Issuable Upon Exercise of Outstanding Warrants Exercise Price Per Share of Common Stock Expiration Date November 2019 Public Offering - Series B 395,528 $ 8.00 May 19, 2027 November 2019 Private Placement - Series B 718,750 $ 8.00 May 19, 2027 December 2017 Public Offering - Series A 160,975 $ 90.00 December 21, 2022 July 2017 Registered Direct Offering 14,270 $ 201.60 January 7, 2024 Consultant 750 $ 116.00 September 11, 2024 Total 1,290,273 Effective May 19, 2022, 1,071,453 Series A warrants issued in the Company's November 2019 public and private securities offerings expired in accordance with the terms of the respective purchase agreement under which the securities had been issued. During the nine months ended September 30, 2021, a combined total of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing $3,856 in cash proceeds. During the nine months ended September 30, 2022, no warrants were exercised by warrant holders. Reserved Shares The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants: September 30, December 31, Stock Options 953,787 722,765 RSUs 27,123 9,430 Warrants 1,290,273 2,361,726 Total number of common shares reserved for future issuance 2,271,183 3,093,921 |
ACCOUNTING POLICIES (Policies)
ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, including accounting standards set by the Financial Accounting Standards Board ("FASB"). The FASB sets GAAP that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the unaudited condensed consolidated financial statements are to the ASC. |
Principles of Consolidation | The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, YOI and Yield10 Bioscience Securities Corp. |
Cash, Cash Equivalents and Restricted Cash | Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents. |
Investments | Investments The Company classifies investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. The Company classifies investments with a maturity date of greater than one year from the balance sheet date as long-term investments. Other-than-temporary impairments of equity investments are recognized in the Company's unaudited condensed consolidated statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates. |
Foreign Currency Translation | Foreign Currency TranslationThe functional currency for YOI is the Canadian dollar. Foreign denominated assets and liabilities of YOI are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the unaudited condensed consolidated balance sheet. When the Company dissolves, sells all or substantially all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its unaudited condensed consolidated statement of operations during the fiscal period when the dissolution or sale occurs. |
Comprehensive Income (Loss) | Comprehensive Loss Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss. |
Income Taxes | Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the unaudited condensed consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized. The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. |
Fair Value Measurements | Fair Value MeasurementsThe carrying amounts of the Company's financial instruments as of September 30, 2022 and December 31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. |
Segment Information | Segment Information The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results. |
Property and Equipment | Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows: Asset Description Estimated Useful Life (years) Equipment 3 Furniture and fixtures 5 Software 3 Leasehold improvements Shorter of useful life or term of lease |
Right-of-Use Assets | Lease Accounting As a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset. |
Grant Revenue | Grant Revenue The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered a central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying unaudited condensed consolidated balance sheets at September 30, 2022 and December 31, 2021. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned. |
Research and Development | Research and Development All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation. Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory. Costs incurred in connection with government research grants are recorded as research and development expense. |
General and Administrative Expenses | General and Administrative Expenses The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation, stock-based compensation and office related expenses incurred to support the administrative and business development of the Company. |
Intellectual Property Costs | Intellectual Property Costs The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the Company's unaudited condensed consolidated statements of operations. |
Stock-based Compensation | Stock-Based CompensationAll share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expenses based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. |
Recent Accounting Standards | Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance . This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU is effective for annual periods beginning after December 15, 2021. The adoption of this standard has not materially impacted the Company’s condensed consolidated financial statements in 2022. The following new pronouncement is not yet effective but may impact the Company's unaudited condensed consolidated financial statements in the future. In June 2016, the FASB issued A SU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition , and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its unaudited condensed consolidated financial statements. |
ACCOUNTING POLICIES (Tables)
ACCOUNTING POLICIES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Schedule of Restricted Cash and Cash Equivalents | The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein: September 30, December 31, Cash and cash equivalents $ 3,922 $ 5,329 Restricted cash 264 264 Total cash, cash equivalents and restricted cash $ 4,186 $ 5,593 |
Schedule of Cash and Cash Equivalents | The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein: September 30, December 31, Cash and cash equivalents $ 3,922 $ 5,329 Restricted cash 264 264 Total cash, cash equivalents and restricted cash $ 4,186 $ 5,593 |
Estimated Useful Lives of Property and Equipment | Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows: Asset Description Estimated Useful Life (years) Equipment 3 Furniture and fixtures 5 Software 3 Leasehold improvements Shorter of useful life or term of lease |
BASIC AND DILUTED NET LOSS PE_2
BASIC AND DILUTED NET LOSS PER SHARE (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares | The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect: As of September 30, 2022 2021 Options 953,787 716,619 Restricted Stock Awards 27,123 9,430 Warrants 1,290,273 2,361,726 Total 2,271,183 3,087,775 |
INVESTMENTS (Tables)
INVESTMENTS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of investment holdings | Investments consist of the following at September 30, 2022 and December 31, 2021: Accumulated Cost at September 30, 2022 Unrealized Market Value at September 30, 2022 Gain (Loss) Short-term investments U.S. government and agency securities $ 3,493 $ — $ (10) $ 3,483 Total $ 3,493 $ — $ (10) $ 3,483 Accumulated Cost at December 31, 2021 Unrealized Market Value at December 31, 2021 Gain (Loss) Short-term investments U.S. government and agency securities $ 10,669 $ — $ (8) $ 10,661 Total $ 10,669 $ — $ (8) $ 10,661 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Assets and liabilities measured at fair value on a recurring basis | The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. Fair value measurements at reporting date using Quoted prices in active markets for identical Significant other Significant Balance as of Description (Level 1) (Level 2) (Level 3) September 30, 2022 Cash equivalents: Money market funds $ 2,594 $ — $ — $ 2,594 Short-term investments: U.S. government and agency securities — 3,483 — 3,483 Total assets $ 2,594 $ 3,483 $ — $ 6,077 Fair value measurements at reporting date using Quoted prices in active markets for identical Significant other Significant Balance as of Description (Level 1) (Level 2) (Level 3) December 31, 2021 Cash equivalents: Money market funds $ 4,878 $ — $ — $ 4,878 Short-term investments: U.S. government and agency securities — 10,661 — 10,661 Total assets $ 4,878 $ 10,661 $ — $ 15,539 |
ACCRUED EXPENSES (Tables)
ACCRUED EXPENSES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Payables and Accruals [Abstract] | |
Schedule of accrued expenses | Accrued expenses consisted of the following at: September 30, December 31, Employee compensation and benefits $ 386 $ 452 Leased facilities 61 71 Professional services 237 264 Field trials and related expenses 342 97 Other 137 252 Total accrued expenses $ 1,163 $ 1,136 |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Summary of option activity | A summary of option activity for the nine months ended September 30, 2022 is as follows: Number of Weighted Average Outstanding at December 31, 2021 722,765 $ 19.22 Granted 233,086 3.83 Exercised — — Forfeited (1,859) 7.55 Expired (205) 4,816.86 Outstanding at September 30, 2022 953,787 $ 14.45 Options exercisable at September 30, 2022 377,807 $ 25.59 |
Schedule of restricted stock units activity | A summary of RSU activity for the nine months ended September 30, 2022 is as follows: Number of RSUs Weighted Average Remaining Contractual Life (years) Outstanding at December 31, 2021 9,430 Awarded 54,250 Released (36,557) Outstanding at September 30, 2022 27,123 0.36 |
LEASES (Tables)
LEASES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Maturity analysis of lease liabilities | At September 30, 2022, the Company's lease liability related to its Woburn facility will mature as follows: Year ended December 31, Undiscounted Cash Flows 2022 (October to December) $ 183 2023 749 2024 771 2025 793 2026 747 Total undiscounted future lease payments 3,243 Amount of lease payments representing interest (460) Total lease liabilities $ 2,783 Short-term lease liability $ 559 Long-term lease liability $ 2,224 |
Lease costs and other information | Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease cost: Operating lease cost $ 151 $ 151 $ 454 $ 454 Short-term lease cost 177 171 509 497 Sublease income (155) (148) (450) (468) Total lease cost, net $ 173 $ 174 $ 513 $ 483 Other information as of: September 30, 2022 December 31, 2021 Weighted-average remaining lease term (years) 4.2 4.9 Weighted-average discount rate 7.25% 7.25% |
GEOGRAPHIC INFORMATION (Tables)
GEOGRAPHIC INFORMATION (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Segment Reporting [Abstract] | |
Schedule of the geographic distribution of revenues and long-lived assets | The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below. Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled. U.S. Canada Total Three Months Ended September 30, 2022 Revenue $ 111 $ — $ 111 Three Months Ended September 30, 2021 Revenue $ 92 $ — $ 92 Nine Months Ended September 30, 2022 Revenue $ 363 $ — $ 363 Nine Months Ended September 30, 2021 Revenue $ 423 $ 39 $ 462 Identifiable long-lived assets September 30, 2022 $ 722 $ 118 $ 840 September 30, 2021 $ 850 $ 53 $ 903 |
CAPITAL STOCK AND WARRANTS (Tab
CAPITAL STOCK AND WARRANTS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Information with regard to outstanding warrants to purchase common stock | The following table summarizes information regarding outstanding warrants to purchase common stock as of September 30, 2022: Issuance Number of Shares Issuable Upon Exercise of Outstanding Warrants Exercise Price Per Share of Common Stock Expiration Date November 2019 Public Offering - Series B 395,528 $ 8.00 May 19, 2027 November 2019 Private Placement - Series B 718,750 $ 8.00 May 19, 2027 December 2017 Public Offering - Series A 160,975 $ 90.00 December 21, 2022 July 2017 Registered Direct Offering 14,270 $ 201.60 January 7, 2024 Consultant 750 $ 116.00 September 11, 2024 Total 1,290,273 |
Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance | The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants: September 30, December 31, Stock Options 953,787 722,765 RSUs 27,123 9,430 Warrants 1,290,273 2,361,726 Total number of common shares reserved for future issuance 2,271,183 3,093,921 |
ACCOUNTING POLICIES - Additiona
ACCOUNTING POLICIES - Additional Information (Details) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 USD ($) segment | Dec. 31, 2021 USD ($) | |
Concentration of credit risk | ||
Restricted cash | $ 264 | $ 264 |
Number of operating segments | segment | 1 | |
Michigan State University | ||
Concentration of credit risk | ||
Accounts and unbilled receivables | $ 76 | $ 198 |
Equipment | ||
Concentration of credit risk | ||
Estimated useful life | 3 years | |
Furniture and fixtures | ||
Concentration of credit risk | ||
Estimated useful life | 5 years | |
Software | ||
Concentration of credit risk | ||
Estimated useful life | 3 years |
ACCOUNTING POLICIES - Schedule
ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Dec. 31, 2020 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 3,922 | $ 5,329 | ||
Restricted cash | 264 | 264 | ||
Total cash, cash equivalents and restricted cash | $ 4,186 | $ 5,593 | $ 14,882 | $ 3,687 |
NATURE OF BUSINESS AND BASIS _2
NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) $ in Thousands | Sep. 30, 2022 USD ($) |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Unrestricted cash and cash equivalents and short-term investments | $ 7,405 |
BASIC AND DILUTED NET LOSS PE_3
BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares | 3 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Antidilutive securities | ||
Antidilutive common stock excluded from the calculation of dilutive shares | 2,271,183 | 3,087,775 |
Options | ||
Antidilutive securities | ||
Antidilutive common stock excluded from the calculation of dilutive shares | 953,787 | 716,619 |
Restricted Stock Awards | ||
Antidilutive securities | ||
Antidilutive common stock excluded from the calculation of dilutive shares | 27,123 | 9,430 |
Warrants | ||
Antidilutive securities | ||
Antidilutive common stock excluded from the calculation of dilutive shares | 1,290,273 | 2,361,726 |
INVESTMENTS (Details)
INVESTMENTS (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Debt Securities, Available-for-sale [Line Items] | ||
Accumulated Cost | $ 10,669 | |
Unrealized Gain | 0 | |
Unrealized (Loss) | (8) | |
Market Value | 10,661 | |
Government securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Accumulated Cost | $ 3,493 | 10,669 |
Unrealized Gain | 0 | 0 |
Unrealized (Loss) | (10) | (8) |
Market Value | $ 3,483 | $ 10,661 |
FAIR VALUE MEASUREMENTS - Asset
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments | $ 10,661 | |
Fair Value, Measurements, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total assets | $ 6,077 | 15,539 |
Fair Value, Measurements, Recurring | U.S. government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments | 3,483 | 10,661 |
Fair Value, Measurements, Recurring | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 2,594 | 4,878 |
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total assets | 2,594 | 4,878 |
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets (Level 1) | U.S. government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments | 0 | 0 |
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets (Level 1) | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 2,594 | 4,878 |
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total assets | 3,483 | 10,661 |
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | U.S. government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments | 3,483 | 10,661 |
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 0 | 0 |
Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total assets | 0 | 0 |
Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | U.S. government and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | $ 0 | $ 0 |
ACCRUED EXPENSES (Details)
ACCRUED EXPENSES (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Payables and Accruals [Abstract] | ||
Employee compensation and benefits | $ 386 | $ 452 |
Leased facilities | 61 | 71 |
Professional services | 237 | 264 |
Field trials and related expenses | 342 | 97 |
Other | 137 | 252 |
Total accrued expenses | $ 1,163 | $ 1,136 |
STOCK-BASED COMPENSATION (Detai
STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||||
Jan. 01, 2022 | May 24, 2021 | Jan. 01, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Stock-based compensation | |||||||
Stock-based compensation | $ 447 | $ 436 | $ 1,458 | $ 1,175 | |||
Weighted Average Exercise Price | |||||||
Number of additional shares authorized | 244,092 | 300,000 | 166,702 | ||||
Additional shares authorized percentage | 5% | ||||||
Number of shares available for grant | 25,961 | 25,961 | |||||
Shares withheld for employee taxes (in shares) | 10,912 | ||||||
Taxes paid on employees' behalf related to vesting of stock awards | $ 34 | ||||||
Employee stock option | |||||||
Stock-based compensation | |||||||
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized | $ 3,567 | $ 3,567 | |||||
Weighted average remaining recognition period (years) | 2 years 6 months 29 days | ||||||
Options | |||||||
Number of Shares | |||||||
Outstanding at the beginning of the period (in shares) | 722,765 | 722,765 | |||||
Granted (in shares) | 233,086 | ||||||
Exercised (in shares) | 0 | ||||||
Forfeited (in shares) | (1,859) | ||||||
Expired (in shares) | (205) | ||||||
Outstanding at the end of the period (in shares) | 953,787 | 953,787 | |||||
Options exercisable at the end of the period (in shares) | 377,807 | 377,807 | |||||
Weighted Average Exercise Price | |||||||
Outstanding at the beginning of the period (in dollars per share) | $ 19.22 | $ 19.22 | |||||
Granted (in dollars per share) | 3.83 | ||||||
Exercised (in dollars per share) | 0 | ||||||
Forfeited (in dollars per share) | 7.55 | ||||||
Expired (in dollars per share) | 4,816.86 | ||||||
Outstanding at the end of the period (in dollars per share) | $ 14.45 | 14.45 | |||||
Options exercisable at the end of the period (in dollars per share) | $ 25.59 | $ 25.59 | |||||
Restricted Stock Awards | |||||||
Weighted Average Exercise Price | |||||||
Shares vested in period (in shares) | 36,557 |
STOCK-BASED COMPENSATION - RSU
STOCK-BASED COMPENSATION - RSU Activity (Details) - Restricted Stock Awards | 9 Months Ended |
Sep. 30, 2022 shares | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | |
Outstanding (in shares) | 9,430 |
Awarded (in shares) | 54,250 |
Released (in shares) | (36,557) |
Outstanding (in shares) | 27,123 |
Weighted average remaining contractual life | 4 months 9 days |
LEASES - Narrative (Details)
LEASES - Narrative (Details) $ in Thousands | 1 Months Ended | ||
Oct. 31, 2016 USD ($) ft² | Sep. 30, 2022 USD ($) ft² | Feb. 29, 2020 USD ($) | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Leased area (in sq ft) | ft² | 22,213 | ||
Undiscounted future lease payments | $ | $ 3,243 | ||
19 Presidential Way | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Letter of credit | $ | $ 229 | ||
Subleased area (in sq ft) | ft² | 9,874 | ||
410 Downey Road and 110 Gymnasium Place | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Leased area (in sq ft) | ft² | 8,600 | ||
CJ CheilJedang Corporation | 19 Presidential Way | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Letter of credit | $ | $ 103 |
LEASES - Maturity Analysis of L
LEASES - Maturity Analysis of Lease Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
2022 (October to December) | $ 183 | |
2021 | 749 | |
2022 | 771 | |
2023 | 793 | |
2024 | 747 | |
Total undiscounted future lease payments | 3,243 | |
Amount of lease payments representing interest | (460) | |
Total lease liabilities | 2,783 | |
Short-term lease liability | 559 | $ 514 |
Long-term lease liability | $ 2,224 |
LEASES - Quantitative Disclosur
LEASES - Quantitative Disclosure of Lease Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Lease cost: | |||||
Operating lease cost | $ 151 | $ 151 | $ 454 | $ 454 | |
Short-term lease cost | 177 | 171 | 509 | 497 | |
Sublease income | (155) | (148) | (450) | (468) | |
Total lease cost, net | $ 173 | $ 174 | $ 513 | $ 483 | |
Other information as of: | |||||
Weighted-average remaining lease term | 4 years 2 months 12 days | 4 years 2 months 12 days | 4 years 10 months 24 days | ||
Weighted-average discount rate | 7.25% | 7.25% | 7.25% |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands | 1 Months Ended | ||
Nov. 12, 2020 | Nov. 30, 2020 | Sep. 30, 2022 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Collaborative agreement, term | 2 years | ||
Grain production guaranteed payments | |||
Other Commitments [Line Items] | |||
Other commitment | $ 320 | ||
Collaborative Arrangement | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Collaborative agreement, quarterly research funding and option fees payable | $ 31 | ||
Collaborative agreement, research funding and option fees payable | $ 250 | $ 31 | |
Collaborative agreement, term of option | 2 years |
GEOGRAPHIC INFORMATION (Details
GEOGRAPHIC INFORMATION (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Geographic Information | |||||
Revenue | $ 111 | $ 92 | $ 363 | $ 462 | |
Identifiable long-lived assets | 840 | 903 | 840 | 903 | $ 890 |
U.S. | |||||
Geographic Information | |||||
Revenue | 111 | 92 | 363 | 423 | |
Identifiable long-lived assets | 722 | 850 | 722 | 850 | |
Canada | |||||
Geographic Information | |||||
Revenue | 0 | 0 | 0 | 39 | |
Identifiable long-lived assets | $ 118 | $ 53 | $ 118 | $ 53 |
CAPITAL STOCK AND WARRANTS - Na
CAPITAL STOCK AND WARRANTS - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | ||||
May 19, 2022 | Feb. 03, 2021 | Sep. 30, 2021 | Sep. 30, 2022 | Dec. 31, 2021 | |
Class of Stock [Line Items] | |||||
Preferred stock, authorized (in shares) | 5,000,000 | 5,000,000 | |||
Preferred stock, par value per share (in dollars per share) | $ 0.01 | $ 0.01 | |||
Warrants expired (in shares) | 1,071,453 | ||||
Proceeds from warrants exercised | $ 3,856 | ||||
Common Stock | |||||
Class of Stock [Line Items] | |||||
Warrants exercised (in shares) | 481,973 | ||||
Public offering | |||||
Class of Stock [Line Items] | |||||
Common stock issued in offering (in shares) | 1,040,000 | ||||
Common stock price (in dollars per share) | $ 12.25 | ||||
Gross proceeds | $ 12,740 | ||||
Issuance costs | $ 747 |
CAPITAL STOCK AND WARRANTS - Sc
CAPITAL STOCK AND WARRANTS - Schedule Of Warrants Issuance (Details) | Sep. 30, 2022 $ / shares shares |
Class of Stock [Line Items] | |
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) | 1,290,273 |
Warrants - expiration January 2024 | |
Class of Stock [Line Items] | |
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) | 14,270 |
Exercise Price (in dollars per share) | $ / shares | $ 201.60 |
Warrants - expiration September 2024 | |
Class of Stock [Line Items] | |
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) | 750 |
Exercise Price (in dollars per share) | $ / shares | $ 116 |
Public offering | Series B Warrants - expiration May 2027 | |
Class of Stock [Line Items] | |
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) | 395,528 |
Exercise Price (in dollars per share) | $ / shares | $ 8 |
Public offering | Series A Warrants - expiration December 2022 | |
Class of Stock [Line Items] | |
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) | 160,975 |
Exercise Price (in dollars per share) | $ / shares | $ 90 |
Private offering | Series B Warrants - expiration May 2027 | |
Class of Stock [Line Items] | |
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) | 718,750 |
Exercise Price (in dollars per share) | $ / shares | $ 8 |
CAPITAL STOCK AND WARRANTS - _2
CAPITAL STOCK AND WARRANTS - Schedule of Common Stock Reserved For Future Issuance (Details) - shares | Sep. 30, 2022 | Dec. 31, 2021 |
Class of Stock [Line Items] | ||
Total number of common shares reserved for future issuance | 2,271,183 | 3,093,921 |
Options | ||
Class of Stock [Line Items] | ||
Total number of common shares reserved for future issuance | 953,787 | 722,765 |
Restricted Stock Awards | ||
Class of Stock [Line Items] | ||
Total number of common shares reserved for future issuance | 27,123 | 9,430 |
Warrants | ||
Class of Stock [Line Items] | ||
Total number of common shares reserved for future issuance | 1,290,273 | 2,361,726 |